Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10709715
    Abstract: Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 14, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10710979
    Abstract: The present invention provides an EGFR kinase inhibitor and a preparation method and use thereof. Specifically, the present invention provides a compound as shown in formula (I), the definition of each group therein being as described in the description. Said compound is an efficient EGFR inhibitor.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: July 14, 2020
    Assignee: ZHEJIANG BOSSAN PHARMACEUTICAL CO. LTD.
    Inventors: Dawei Ma, Qiang Yu, Junying Yuan, Hongguang Xia, Dongpo Cai, Kailiang Wang, Chen Zhang, Shanghua Xia
  • Patent number: 10696695
    Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 30, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Alexandra M. Courtis, James Adam Hendricks
  • Patent number: 10696658
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 30, 2020
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Patent number: 10696677
    Abstract: This disclosure is directed to various compounds and methods of preparation of improved compounds that are capable of functioning as cannabinoid receptor 1 (CB1) antagonists with reduced central nervous system (CNS) side effects. The application is also directed to pharmaceutical compositions containing one or more of these compounds, which may also contain one or more additional therapeutic agents. It is also directed to methods of treatment of various conditions that may be responsive to antagonism of the CB1 receptors, including, but not limited to, metabolic syndromes (including liver disease, obesity, and diabetes).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 30, 2020
    Assignee: Research Triangle Institute
    Inventors: Rangan Maitra, Robert W. Wiethe, Yanan Zhang, George S. Amato
  • Patent number: 10696693
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure Formula (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, X, R1, R2 m, p and a are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 30, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Todd Kinsella, Jiaxin Yu, Marina Gelman, Ihab S. Darwish
  • Patent number: 10696665
    Abstract: The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 30, 2020
    Assignee: Eli Lilly and Company
    Inventors: Wenceslao Lumeras Amador, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, Raymond Gilmour, Patric James Hahn, Renato Alejandro Bauer, Zoran Rankovic
  • Patent number: 10683303
    Abstract: Processes are provided for the production of methenamine mandelate that do not require the isolation of produced methenamine prior to production of the methenamine mandelate.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: June 16, 2020
    Assignee: ALBEMARLE CORPORATION
    Inventors: Bryce Kelly Assink, Tino Jon Caviggiola, III
  • Patent number: 10676463
    Abstract: There are provided a novel isocyanurate compound having a glycidyl group as a substituent to be bonded to a nitrogen atom. A monoglycidyl isocyanurate compound of the following Formula (1), (2), or (3). (wherein two R1s are each a C2-10 alkyl group, two R2s are each a C1-5 alkylene group, two R3s are each a C1-2 alkyl group, two R4s are each a C1-2 alkylene group, and two R5s are each a C1-2 alkyl group).
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 9, 2020
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Yuichi Goto, Masahisa Endo, Gun Son
  • Patent number: 10676478
    Abstract: The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 9, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Lifang Wu, Hao Wu, Shuhui Chen, Ling Yang
  • Patent number: 10672993
    Abstract: The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 2, 2020
    Assignee: LT MATERIALS CO., LTD.
    Inventors: Young-Seok No, Kee-Yong Kim, Hyo-Kyun Ham, Jin-Seok Choi, Dae-Hyuk Choi, Sung-Jin Eum, Joo-Dong Lee
  • Patent number: 10669475
    Abstract: Surface-modified nanoparticles are produced by associating ligand interactive agents with the surface of a nanoparticle. The ligand interactive agents are bound to surface modifying ligands that are tailored to impart particular solubility and/or compatibility properties. The ligand interactive agents are crosslinked via a linking/crosslinking agent, such as hexamethoxymethylmelamine or a derivative thereof. The linking/crosslinking agent may provide a binding site for binding the surface modifying ligands to the ligand interactive agents.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: June 2, 2020
    Assignee: Nanco Technologies Ltd.
    Inventor: Imad Naasani
  • Patent number: 10662195
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 26, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Patent number: 10662161
    Abstract: The various examples presented herein are directed to compounds of the Formula: wherein R1-R5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 26, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Sunil Abraham David, Mallesh Beesu
  • Patent number: 10639312
    Abstract: The present invention contemplates a high dose finished pharmaceutical dosage form comprising a methenamine salt, such as methenamine mandelate, as an active pharmaceutical ingredient wherein the methenamine salt API has a moisture content that is less than the upper limit specified in the USP. A preferred embodiment of the present invention has a moisture content that is half of the limit set forth in the USP for each particular methenamine salt. An even more preferred embodiment has a moisture content of less than or equal to one-tenth of a percent (0.1%), regardless of the methenamine salt. The present invention may include one or more pharmaceutically acceptable ingredients. The present invention also contemplates a moisture content of the high dose finished pharmaceutical dosage form that is less than one percent.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 5, 2020
    Assignee: Edenbridge Pharmaceuticals, LLC
    Inventor: Robert O'Connor
  • Patent number: 10636979
    Abstract: The present invention relates to heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Tobias Grossmann, Jonas Valentin Kroeber
  • Patent number: 10633368
    Abstract: Provided is a synthesis method for a voriconazole intermediate condensate as shown in formula II or an acid addition salt thereof. As shown in reaction formula 1, the product is prepared via compounds III and IV. The synthesis method adjusts the feeding means, and the reaction conditions are mild and controllable, thereby reducing the production of impurity A, avoiding the use of highly toxic metal lead, and eliminating the risk of highly toxic metal remaining in a drug. The product has a higher purity and significant industrial application value.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: April 28, 2020
    Assignee: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    Inventors: Hu Huang, Wenfeng Huang, Guoliang Tu, Jiegen Liu, Zhongming Xu, Qianghui Wu, Zhaoyang Meng, Yuling Fang
  • Patent number: 10626097
    Abstract: The present invention relates to an improved process for making hydroxyethyl piperazine compounds especially mono-hydroxyethyl piperazine. The improvement comprises reacting piperazine and an alkylene oxide, preferably ethylene oxide in a reactive distillation column.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: April 21, 2020
    Assignee: Dow Global Technologies LLC
    Inventors: John G. Pendergast, Jr., Ravindra S. Dixit, Stephen W. King, Christophe R. Laroche
  • Patent number: 10626110
    Abstract: The present disclosure provides a crystalline form F of Pazopanib HCl, which is characterized by an X-ray diffraction (XRD) pattern having peaks at about 11.3, 14.6, 16.9, 19.5, 19.7, 23.5 and 25.9°±0.2° 2?. The present disclosure also provides a preparation process of a crystalline form F of Pazopanib HCl.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 21, 2020
    Assignee: FORMOSA LABORATORIES, INC.
    Inventor: Sheng-Kai Ko
  • Patent number: 10617690
    Abstract: The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 14, 2020
    Assignee: WUXI FORTUNE PHARMACEUTICAL CO., LTD
    Inventors: Hao Wu, Weiwei Mao, Lili Fan, Charles Z. Ding, Shuhui Chen, Fei Wang, Guoping Hu, Jian Li